Drugs / Atamestane
Atamestane
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00267553 | Nov 2005 → Jun 2006 | breast neoplasm | Intarcia Therapeutics | Terminated | No outcome recorded |
| Phase 3 | NCT00097344 | Dec 2004 → Aug 2006 | breast neoplasm | Intarcia Therapeutics | Terminated | No outcome recorded |
| Phase 3 | NCT00044291 | Jun 2002 → Jan 2006 | breast neoplasm | Intarcia Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT00010322 | Oct 2000 → May 2001 | breast cancer | Intarcia Therapeutics | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | atamestane | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00010322 ↗ |
| Known as | Atamestano | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105987 ↗ |
| Known as | SH-489 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105987 ↗ |
| Action | Inhibit | “Atamestane may fight breast cancer by blocking the production of estrogen.” NCT00010322 ↗ |
| Modality | Small molecule | — CHEMBL2105987 ↗ |
| Route | Oral | “Arm I: Patients receive oral toremifene daily and oral atamestane twice daily.” NCT00010322 ↗ |